Phenethylaminylation: Preliminary Evidence for the Covalent Transamidation of Psychedelic Phenethylamines to Glial Proteins using 3,5-Dimethoxy-4-(2-Propynyloxy)-Phenethylamine as a Model Compound.

Psychedelics are well known for their ability to produce profoundly altered states of consciousness. But, more importantly, the effects of psychedelics can influence neurobehavioral changes that last well after these acute subjective effects end. This phenomenon is currently being leveraged in the development of psychedelic-assisted psychotherapies for the treatment of multiple neuropsychiatric disorders.

N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)-A Prognostic Biomarker in Older and/or Frail Adults with Advanced Gastroesophageal Cancer: A Post Hoc Analysis of the GO2 Clinical Trial.

Better prognostic biomarkers are needed in older adults with cancer. There are established links between N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) and sarcopenia, and sarcopenia is associated with poorer cancer survival. However, there are limited data regarding baseline NT-proBNP as a biomarker of cancer outcome.

Reactions to undesired outcomes: Evidence for the opposer's loss effect.

The present research identifies a psychological phenomenon that helps to explain how people who prefer the same option to the same degree (e.g., two people equally prefer Politician A over Politician B) can differ in their negativity toward the same undesired outcome (e.

Improving recruitment and retention of people with Parkinson's disease to clinical studies: A scoping review.

Background: Timely recruitment and effective retention of participants are challenging for clinical Parkinson's disease (PD) research studies. Not achieving this can affect delivery costs and bias results.

Objective: To identify successful recruitment and retention methodologies for clinical research studies in PD.

UK cancer vaccine advance - Recognising and realising opportunities.

Vaccines have revolutionised the field of medicine, eradicating and controlling many diseases. Recent pandemic vaccine successes have highlighted the accelerated pace of vaccine development and deployment. Leveraging this momentum, attention has shifted to cancer vaccines and personalised cancer vaccines, aimed at targeting individual tumour-specific abnormalities.